ACR 2021
Community Rheumatology Clinics: Pegloticase Safe & Effective With Any Immunomodulator
Nov 30, 2021
Pegloticase is effective for lowering serum urate patients with uncontrolled or refractory gout, although more than half of patients experience anti-drug antibody development which limits its efficacy.1 Administering pegloticase...
Read MoreAdding Methotrexate to Pegloticase Nearly Doubles Gout Response Rate
Nov 29, 2021
MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Physician’s Weekly spoke with...
Read MoreACR: Therapy of PsA: No Benefit of Adding Methotrexate to IL-12/IL-23 Inhibitor
Nov 17, 2021
Patients with active psoriatic arthritis are better off with monotherapy with ustekinumab compared with the combination of methotrexate and ustekinumab. The combination causes more side effects and does not enhance efficacy or...
Read MoreACR: Cycling JAK Inhibitors & Switching to a bDMARD Show Similar Effectiveness in RA
Nov 17, 2021
People with difficult-to-treat rheumatoid arthritis who do not have success with one JAK inhibitor could succeed either by cycling to other JAK inhibitors or switching to a biologic. Both strategies led to comparable control of...
Read MoreACR: A New Xanthine Oxidase Inhibitor for Gout on the Horizon
Nov 17, 2021
Tigulixostat was successfully tested in patients with gout and hyperuricemia for its serum urate-lowering capacity. The drug was overall well tolerated and without particular safety signals. These results support dose finding...
Read MoreACR: Laboratory & Clinical Data Predict the Development of Multisystem Inflammatory Syndrome in Children
Nov 17, 2021
A retrospective chart review analysis in the first 24 hours after hospital admission revealed four predictors that discriminate between children with multisystem inflammatory syndrome and other syndromes: hypotension, abdominal...
Read MoreACR: Antifibrotic Agent Slows Progression in RA-Associated Interstitial Lung Disease
Nov 17, 2021
Patients with rheumatoid arthritis and associated interstitial lung disease could be safely treated with pirfenidone, the TRAIL1 study showed. In participants receiving the antifibrotic, lung function decline was slowed down,...
Read MoreImmunomodulators Enhance Therapy Persistence of Pegloticase in Gout
Nov 15, 2021
Concomitant use of immunomodulators prolonged the effectiveness of pegloticase in patients with uncontrolled gout. Results from a large observational study were consistent with previously conducted smaller trials.1 The...
Read MoreACR: Higher Dosing of Hydroxychloroquine Ups Risk for Retinopathy
Nov 15, 2021
The likelihood of developing retinopathy on hydroxychloroquine medication is markedly increased by several independent risk factors, including long-term use and high-dose regimens. Also, the presence of chronic kidney disease...
Read MoreACR: Statin Use in RA: Benefits Outweigh Diabetes Risk
Nov 15, 2021
New data on the advantages and disadvantages of statins for patients with rheumatoid arthritis showed significant reductions in cardiovascular and all-cause mortality but an increased risk for type 2 diabetes mellitus. Not all...
Read MoreACR: More Breakthrough Infection After COVID-19 Vaccination in Patients With Rheumatic Diseases
Nov 15, 2021
Several autoimmune or inflammatory rheumatic diseases are associated with an increased risk for experiencing a breakthrough COVID-19 infection, despite complete vaccination. The risk varies according to the type of diagnosis and...
Read MoreACR: Nearly One-Third of Patients With Lupus Not Sufficiently Protected by COVID-19 Vaccine
Nov 15, 2021
A multi-ethnic cohort study demonstrates that 29% of patients with lupus had an inadequate response to the COVID-19 vaccines. Interestingly, patients taking anti-malarials showed an almost 12-times improved response. Overall...
Read MoreACR: COVID-19 mRNA Vaccine Safe in Immunosuppressed Adults With Autoimmune Disease
Nov 15, 2021
The Moderna mRNA 1273 SARS-CoV-2 vaccine is safe in immunosuppressed adults with autoimmune disease and not associated with severe disease flares. However, therapy with mycophenolate mofetil and rituximab is associated with a...
Read MoreACR 2021 Features Sessions
Nov 2, 2021
Keynote Lecture: The Covidization of Rheumatology: What Will or Won’t Change Beyond the COVID-19...
Read MoreACR Convergence 2021 Accepted Abstracts
Nov 2, 2021
Accepted abstracts will be published in an online supplement of the Arthritis & Rheumatology journal. Accepted and late-breaking abstracts are also available on the ACR Convergence Meeting Abstracts website. Check out...
Read MoreACR Convergence 2021 Preview & Program
Nov 2, 2021
The ACR’s first-rate education program showcases cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence...
Read MoreInitial Pegloticase Serum Levels Predict Responsiveness in Patients With Chronic Gout
Oct 28, 2021
In patients with chronic refractory gout whose serum urate (SU) was not maintained at ≤6 mg/dL, adding an additional tolerizing dose of pegloticase between the first and second biweekly administrations showed an overall response...
Read MorePegloticase Treatment Significantly Decreased BP in Patients With Chronic Gout
Oct 28, 2021
Serum urate (SU) responders to pegloticase experienced significant reductions in mean arterial pressure (MAP) that were independent of changes in renal function, according to prior randomized clinical trials (RCTs). To determine...
Read MoreEfficacy & Safety Shown in Pegloticase With Concomitant IMM
Oct 28, 2021
Small clinical trials have shown that concomitant immunomodulatory (IMM) drug use improves pegloticase persistence in the treatment of gout. However, real-world evidence has been lacking. Therefore, researchers evaluated...
Read More- 1
- 2